Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer Metastatic 1 Neoplasms 1

Interventions

enzalutamide 7 Prednisone 7 cabazitaxel 6 Radiosurgery 6 Docetaxel 5 Androgen Antagonists 4 Abiraterone Acetate 4 XRP6258 2 Standard of Care 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 pembrolizumab 1 olaparib 1 gallium 68 PSMA-11 1 fludrocortisone acetate 1 darolutamide 1 apalutamide 1 Zuclomiphene 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisolone 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Midazolam 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 LY3023414 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × fludrocortisone acetate × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡